Vuno Inc. announced that it has entered into a memorandum of understanding with DongKoo Bio&Pharma Co., Ltd. (KOSDAQ:A006620) and received KRW 3,000,000,000 in a round of funding on May 19, 2020. The company is pushing for an initial public offering within 2020.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
31,050 KRW | +1.14% | +9.33% | -26.07% |
03-26 | Vuno Inc. announced that it has received KRW 10.4 billion in funding | CI |
03-21 | Vuno Inc. announced that it expects to receive KRW 10.4 billion in funding | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.07% | 312M | |
+15.21% | 3.94B | |
+2.59% | 3.07B | |
-32.56% | 1.62B | |
-56.31% | 766M | |
-25.74% | 610M | |
-12.88% | 339M | |
-10.90% | 210M | |
-2.33% | 201M | |
-19.35% | 143M |
- Stock Market
- Equities
- A338220 Stock
- News Vuno Inc.
- Vuno Inc. announced that it has received KRW 3 billion in funding from DongKoo Bio&Pharma Co., Ltd.